GSK in­vests $270M in­to vac­cine man­u­fac­tur­ing in Bel­gium

GSK is in­vest­ing about $270 mil­lion (€250 mil­lion) to build out and ex­pand its vac­cine man­u­fac­tur­ing fa­cil­i­ties in Wavre, Bel­gium.

The plant is ex­pect­ed to have two wings: one for pro­duc­ing its “non-live” vac­cines, in­clud­ing the new­ly ap­proved RSV vac­cine Arexvy and the shin­gles vac­cine Shin­grix, and the oth­er wing will make “live” vac­cines, in­clud­ing Var­il­rix for chick­en­pox and Pri­or­ix for measles.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.